Discontinuation report MYLAN-BUPRENORPHINE/NALOXONE
Report ID | 94048 |
Drug Identification Number | 02408104 |
Brand name | MYLAN-BUPRENORPHINE/NALOXONE |
Common or Proper name | BUPRENORPHINE/NALOXONE |
Company Name | MYLAN PHARMACEUTICALS ULC |
Market Status | CANCELLED POST MARKET |
Active Ingredient(s) | BUPRENORPHINE NALOXONE |
Strength(s) | 8MG 2MG |
Dosage form(s) | TABLET |
Route of administration | SUBLINGUAL |
Packaging size | 100BT |
ATC code | N07BC |
ATC description | DRUGS USED IN ADDICTIVE DISORDERS |
Reason for discontinuation | Business reasons |
Anticipated discontinuation date | 2019-09-17 |
Actual discontinuation date | 2019-09-17 |
Remaining supply date | 2019-09-17 |
Discontinuation status | Discontinued |
Discontinuation decision reversal | No |
Information on remaining supply | |
Company comments | Discontinued in Shortage ID 3089. Last lot 3085363 exp 2019-05-31 |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 85 ADVANCE ROAD ETOBICOKE, ONTARIO CANADA M8Z 2S6 |
Company contact information | Mylan Pharmaceuticals ULC, 85 Advance Road, Etobicoke, ON, M8Z 2S6 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v3 | 2019-09-18 | English | Compare |
v2 | 2019-09-17 | French | Compare |
v1 | 2019-09-17 | English | Compare |
Showing 1 to 3 of 3